You are here


February 18, 2010
RV144 Update at CROI

COL Nelson Michael, MHRP Director, made a presentation today at the 17th Conference on Retroviruses and Opportunistic Infections (CROI 2010) in San Francisco, California. COL Michael showed some new data on risk factors and breakthrough infections. He also shared some ideas on the way forward for HIV vaccine development. 

MHRP has formed four scientific working groups to help guide...

January 28, 2010
Paper published on Phase I/II Study of a Vaccine Candidate in East Africa

RV 172: A Phase I/II Clinical Trial to Evaluate the Safety and Immunogenicity of a Multiclade HIV-1 DNA Plasmid Vaccine, VRC-HIVDNA016-00-VP, Boosted by a Multiclade HIV-1 Recombinant ADENOVIRUS-5 Vector Vaccine, VRC-HIVADV014-00-VP in HIV Uninfected Adu


Results from the RV172 study of a vaccine candidate in East Africa conducted by MHRP were published recently in the Journal...

January 15, 2010
RV144 Vaccine Regimen Tops Best of Lists in 2009

The RV144 vaccine regimen used in the Phase III HIV vaccine clinical trial in Thailand was rated number two on TIME magazine’s Top 10 Medical Breakthroughs list for 2009 and number eight on their 50 Best Inventions of the Year.

The vaccine also made Scientific American’s top 10 science stories, Discover magazine’s top 100 science stories (ranked number 13) and Infectious Disease News’...

December 14, 2009
New Insight into Selective Binding Properties of Infectious HIV

Free infectious HIV-1 is widely thought to be the major form of the virus in the blood of infected persons. U.S. Military HIV Research Program (MHRP) researchers, however, have demonstrated that essentially all of the infectious virus particles can bind to the surface of red blood cells isolated from each of 30 normal (non-infected) human donors. The results were published on today in PLoS ONE...

December 11, 2009
Phase Ib Ebola/Marburg Vaccine Clinical Trial Begins

MHRP began a collaborative Phase Ib study to evaluate the safety and immunogenicity of Ebola and Marburg DNA plasmid vaccines in healthy adults in Kampala, Uganda.

This study, called RV247, is a randomized, double-blinded, placebo-controlled study that will evaluate the safety, tolerability, and immunogenicity of two recombinant DNA vaccines: one against Ebola virus and one against...

December 10, 2009
U.S. Ambassador to Tanzania Visits MHRP site in Mbeya

The U.S. Ambassador to the United Republic of Tanzania, Alfonso E. Lenhardt, visited MHRP in Mbeya, TZ November 22-24, 2009. The Ambassador toured the state-of-the-art laboratories, gaining appreciation for the work MHRP carries out in partnership with the civilian hospitals, NGOs, and the Mbalizi Tanzania People’s Defense Forces Hospital.

The Ambassador also met with representatives...

December 8, 2009
World AIDS Day Events

Scientific Collaboration at WRAIR

Walter Reed Army Institute of Research (WRAIR) and MHRP hosted an event to highlight recent achievements in HIV research and share program successes from the PEPFAR program in Kenya. Dr. Merlin Robb, MHRP clinical deputy director, provided a Phase III HIV vaccine trial update, before turning the stage over to Keynote Speaker Dr. David Margolis,...

December 3, 2009
Ugandan Youth Create Murals to Help Promote HIV Prevention

The Kayunga Youth Center helped design murals that are helping with HIV prevention in their community in rural Uganda. The Youth Center is part of the PEPFAR program at MHRP's Uganda site, known locally as the Makerere University Walter Reed Project. The images used on the murals seem to have a positive effect on other youth in the community, effectively conveying key messages in HIV...

November 16, 2009
MHRP Researcher Receives HIV Prevention Research Advocacy Fellowship

MHRP’s Jauhara Nanyondo, from the Makerere University Walter Reed Program in Uganda, was among ten individuals selected by the AIDS Vaccine Advocacy Coalition (AVAC) to receive a 12-month Research Advocacy Fellowship.


During her fellowship, Jauhara will develop a standard training curriculum on HIV vaccine research for the media in Uganda. The media can be a strong advocacy...

November 6, 2009
Interview with Ambassador Goosby, U.S. Global AIDS Coordinator

What has the United States done to combat global HIV/AIDS since PEPFAR’s launch in 2003?

As the largest commitment in history by any nation to combat a single disease, providing more than $25 billion to the fight against global AIDS, the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) has had numerous achievements in the past six years. For instance, today, an estimated four...